Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy

Area of Science:

• Oncology
• Molecular Biology
• Cell Death Mechanisms

Background:

• Colon cancer cells exhibit p53-dependent cell death pathways.
• Mitochondrial dysfunction is implicated in cancer progression and treatment response.
• Novel therapeutic strategies targeting specific cell death mechanisms are needed.

Purpose of the Study:

• To identify the key regulator of p53-dependent cell death induced by the gallium-based anticancer drug KP46 in colon cancer cells.
• To elucidate the mechanism of KP46 action, focusing on its mitochondrial effects and interaction with iron metabolism.
• To explore the potential of targeting BNIP3L as a novel anticancer strategy.

Main Methods:

• Treatment of colon cancer cells with KP46.
• Assessment of mitochondrial morphology, function, and dynamics.
• Measurement of intracellular iron and heme levels.
• Analysis of p53 localization and transcriptional activity.
• Investigation of BNIP3L expression and its role in apoptosis and mitophagy.
• Evaluation of cell viability upon KP46 exposure and BNIP3L modulation.

Main Results:

• KP46 accumulated in mitochondria, causing p53-dependent damage and impairing bioenergetics.
• KP46 reduced intracellular iron and heme, leading to nuclear p53 accumulation.
• p53 activated BNIP3L, a BH3-only protein, which sensitized mitochondrial permeability transition.
• Upregulated BNIP3L induced Parkin-mediated mitophagy and cellular vacuolization.
• Downregulation of BNIP3L rescued cell viability, confirming its role in KP46-induced cell death.

Conclusions:

• BNIP3L is the key regulator of p53-dependent cell death in colon cancer cells treated with KP46.
• KP46 acts by depleting iron, activating p53, and inducing BNIP3L-mediated mitophagy.
• Targeting BNIP3L represents a novel anticancer strategy for wild-type p53 colon cancers, leveraging iron depletion and mitophagy pathways.